Review of CISPOLY's Academic Achievements in 2024
CISPOLY's cervical cancer and endometrial cancer methylation detection technology has received Class III medical device certifications from the National Medical Products Administration (NMPA). CISPOLY has collaborated with experts nationwide to collect and analyze clinical application data, publishing multiple papers in domestic journals and international SCI journals, receiving significant recognition and achieving remarkable results. Domestic experts, based on evidence-based medicine, have cited relevant findings and developed cervical cancer and endometrial cancer screening and management guidelines and expert consensus, making this new domestic technology an important component of clinical testing and practice. We thank gynecologists nationwide for their recognition of CISPOLY products. Looking back at CISPOLY's academic achievements in 2024, we look forward to more physicians joining CISPOLY in 2025 to explore the gynecologic oncology field together, jointly publishing research findings on gynecologic tumor screening, and safeguarding the health of women nationwide.
CISPOLY's selected gynecologic tumor methylation detection genes have been featured in "top international medical journals": Recognized by global experts!
01 Cervical Cancer Methylation-Related Guidelines, Expert Consensus, and Publications
-
PAX1 and JAM3 Dual Genes Included in the * Chinese Cervical Cancer Screening Guidelines (Part II) Guiding Clinical Application of Cervical Cancer 2. JAM3/PAX1 Hypermethylation for Diagnosing High-Grade Cervical Lesions in High-Risk HPV-Infected Patients
-
First Revealing the Clinical Value of PAX1/JAM3 Methylation in Persistent HPV Infection
-
Research Progress on Methylation Testing for Cervical Cancer Screening and Prognostic Management
-
Evaluating the Screening Role of PAX1/JAM3 Methylation in HPV 16/18-Infected Women Click the blue text above to jump to the original article links. 02 Endometrial Cancer Methylation-Related Publications
-
Expert Consensus on Tumor DNA Methylation Marker Detection and Clinical Application Formulating and Recommending Clinical Pathways for Cervical Cancer and Endometrial Cancer DNA Methylation Screening
-
Application Value of DNA Methylation Testing in Endometrial Cancer Screening for Postmenopausal Women
https://www.international-journal-of-gynecological-cancer.com/article/S1048-891X(24)00021-5/abstract
- Application Value of DNA Methylation Testing in Endometrial Cancer Diagnosis for Reproductive-Age Women with Abnormal Uterine Bleeding
https://rs.yiigle.com/CN112137202312/1450801.htm
- Hypermethylated CDO1 and CELF4 in Cytological Specimens as Triage Strategy Biomarkers for Endometrial Malignant Lesions
https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2023.1289366/full
- Application Value of CISENDO® Dual-Gene Methylation Testing in Endometrial Cancer Screening
https://d.wanfangdata.com.cn/periodical/lanzyxyxb202407004
03 Ovarian Cancer Methylation-Related Publications
1. JH | Significance of Elevated CDO1 Gene and HOXA9 Gene Promoter Methylation in Serum for Ovarian Cancer Diagnosis
Beijing Origin CISPOLY Biotechnology Co., Ltd. is a technology-driven enterprise committed to health innovation. As a pioneer in the field of early gynecologic oncology diagnosis, CISPOLY has developed early-detection products for cervical cancer, endometrial cancer, and ovarian cancer using proprietary technologies and patent-protected biomarkers, filling a critical gap in the field.
As women pay increasing attention to their own health, the women's health market holds great potential. Beyond the early screening and diagnosis product pipeline for gynecologic oncology, CISPOLY will continue to build additional women's health product lines, establishing itself as a technology-innovation-leading enterprise in the women's health market.